AMLX vs. OPTN, CNTX, KPTI, PDSB, NVCT, VTGN, RNAC, DMAC, COYA, and MCRB
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include OptiNose (OPTN), Context Therapeutics (CNTX), Karyopharm Therapeutics (KPTI), PDS Biotechnology (PDSB), Nuvectis Pharma (NVCT), Vistagen Therapeutics (VTGN), Cartesian Therapeutics (RNAC), DiaMedica Therapeutics (DMAC), Coya Therapeutics (COYA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Amylyx Pharmaceuticals has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.
Amylyx Pharmaceuticals has higher revenue and earnings than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amylyx Pharmaceuticals has a net margin of -17.86% compared to OptiNose's net margin of -41.55%. Amylyx Pharmaceuticals' return on equity of 4.14% beat OptiNose's return on equity.
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
OptiNose received 220 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 63.31% of users gave OptiNose an outperform vote while only 62.50% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals presently has a consensus price target of $28.67, suggesting a potential upside of 1,466.48%. OptiNose has a consensus price target of $3.67, suggesting a potential upside of 191.01%. Given Amylyx Pharmaceuticals' higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than OptiNose.
In the previous week, OptiNose had 13 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 21 mentions for OptiNose and 8 mentions for Amylyx Pharmaceuticals. OptiNose's average media sentiment score of 0.21 beat Amylyx Pharmaceuticals' score of 0.14 indicating that OptiNose is being referred to more favorably in the news media.
Summary
Amylyx Pharmaceuticals and OptiNose tied by winning 9 of the 18 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
